Literature DB >> 8617944

CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C.

J M Teng1, X R Liu, G B Mills, B Dupont.   

Abstract

The human leukemic cell line YT displays spontaneous cytotoxicity against CD80+ and/or CD86+ and ICAM-1+ target cells. In this work, we report that CD28-mediated cytotoxicity of YT involves tyrosine phosphorylation and activation of phosphatidylinositol (PI) 3-kinase, the Tec kinase Itk/Emt, and protein kinase C (PKC). YT mediates lysis of CD80+/CD86+ B lymphoblastoid cell lines and the murine mastocytoma p815 transfected with CD80 or CD86. The lysis was inhibited by two different Pi 3-kinase inhibitors, wortmannin and LY294002. The PKC inhibitors calphostin C and bisindolylmaleimide GF109203X also abolished YT-mediated cytotoxicity. Furthermore, exocytosis of cytolytic effector molecules was also inhibited by PI 3-kinase inhibitors and PKC inhibitors. PMA together with Ionomycin did not induce granule exocytosis or cytotoxicity by YT cells. Treatment of YT cells with PMA for up to 20 h, which depleted PMA-responsive PKC isoforms, had no effect on the CD28-mediated cytotoxicity. This cytotoxicity displayed by PMA-treated YT cells, however, could still be inhibited by Pi 3-kinase inhibitors and PKC inhibitors. Taken together, these results are consistent with a model in which activation of CD28 and LFA-1 induces tyrosine phosphorylation of the CD28 cytoplasmic domain, recruitment and activation of PI 3-kinase, as well as the Tec kinase Itk/Emt, and the activation of PMA-nonresponsive PKC isoenzymes. Activation of PI 3-kinase and PMA-nonresponsive PKC isoenzymes is shown to be involved directly in cytolytic granule release by YT cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617944

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription.

Authors:  Z Li; G J Nabel
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

2.  CD28-stimulated ERK2 phosphorylation is required for polarization of the microtubule organizing center and granules in YTS NK cells.

Authors:  Xi Chen; David S J Allan; Konrad Krzewski; Baoxue Ge; Hernan Kopcow; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

3.  Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor.

Authors:  Linda Monaco-Shawver; Lynnae Schwartz; Florin Tuluc; Chang-Jiang Guo; Jian Ping Lai; Satya M Gunnam; Laurie E Kilpatrick; Pinaki P Banerjee; Steven D Douglas; Jordan S Orange
Journal:  J Leukoc Biol       Date:  2010-10-12       Impact factor: 4.962

4.  Evidence that a kinase distinct from protein kinase C and phosphatidylinositol 3-kinase mediates ligation-dependent serine/threonine phosphorylation of the T-lymphocyte co-stimulatory molecule CD28.

Authors:  R V Parry; D Olive; J Westwick; D M Sansom; S G Ward
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

5.  Involvement of protein kinase C-delta in CD28-triggered cytotoxicity mediated by a human leukaemic cell line YT.

Authors:  F J Kos; H D Bear
Journal:  Immunology       Date:  1998-08       Impact factor: 7.397

6.  T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells.

Authors:  K Q Liu; S C Bunnell; C B Gurniak; L J Berg
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

Review 7.  CAR-NK cells for cancer immunotherapy: from bench to bedside.

Authors:  Leisheng Zhang; Yuan Meng; Xiaoming Feng; Zhongchao Han
Journal:  Biomark Res       Date:  2022-03-18

8.  Cdc42-interacting protein-4 functionally links actin and microtubule networks at the cytolytic NK cell immunological synapse.

Authors:  Pinaki P Banerjee; Rahul Pandey; Rena Zheng; Megan M Suhoski; Linda Monaco-Shawver; Jordan S Orange
Journal:  J Exp Med       Date:  2007-09-04       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.